| dc.contributor.author | Gutiérrez Saborido, Daniel | |
| dc.contributor.author | Gutiérrez-Valencia, Alicia | |
| dc.contributor.author | González Domenech, Carmen María | |
| dc.contributor.author | López Ruz, Miguel Ángel | |
| dc.contributor.author | Raffo Márquez, Miguel | |
| dc.contributor.author | Omar, Mohamed | |
| dc.contributor.author | Girón González, José Antonio | |
| dc.contributor.other | Medicina | es_ES |
| dc.date.accessioned | 2024-11-21T11:01:38Z | |
| dc.date.available | 2024-11-21T11:01:38Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 1432-0584 | |
| dc.identifier.issn | 0939-5555 | |
| dc.identifier.uri | http://hdl.handle.net/10498/33880 | |
| dc.description.abstract | The change in the incidence of lymphomas in function of the presence or absence of sustained virological response after anti-hepatitis C therapy in a cohort of human immunodeficiency (HIV)-hepatitis C (HCV) viruses coinfected patients was analyzed. A prospective cohort of 755 HIV-HCV coinfected patients who received their first anti-HCV therapy, based on interferon + ribavirin schemas, was evaluated. Incidence and histologic types of lymphomas were analyzed in two periods: (1) before administration of anti-HCV therapy and (2) after anti-HCV therapy. The association between lymphoma incidence and demographic, HIV- (minimum CD4+ cell count and CD4+ cell count at diagnosis of lymphoma, antiretroviral therapy, maximal HIV load and HIV load at diagnosis of lymphoma) and HCV-related variables (HCV load, genotype, sustained viral response to anti-HCV therapy) were analyzed. A total of 13 lymphomas [incidence rate (95% confidence interval), 0.72 (0.33-1.11) × 1000 person-years, time from HIV diagnosis to lymphoma diagnosis (median, interquartile range), 15 (11-19) years] were diagnosed. Nine of them were non-Hodgkin and four Hodgkin lymphomas. The median CD4+ T cell count at diagnosis of lymphoma was 457/mm3, with only two cases with values lower than 200/mm3. The incidence rate of non-Hodgkin lymphomas was similar pre- and post-anti HCV therapy [0.33 (0.00-0.65) vs 0.68 (0.08-1.26) × 1000 person-years, respectively, p > 0.05]. Patients with sustained virologic HCV response showed similar incidence rate of lymphomas than that of those without anti-HCV response. In conclusion, anti-HCV therapy does not modify the incidence rate of lymphomas in HIV-HCV coinfected patients. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | SPRINGER | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.source | Ann Hematol. 2019 Aug;98(8):1953-1959. | es_ES |
| dc.subject | HIV | es_ES |
| dc.subject | Hepatitis C virus | es_ES |
| dc.subject | Non-Hodgkin lymphoma | es_ES |
| dc.subject | Hodgkin lymphoma | es_ES |
| dc.subject | Interferon alpha | es_ES |
| dc.subject | Ribavirin | es_ES |
| dc.title | Incidence of lymphoma in HIV-HCV-infected patients. Modifications in function of the anti-hepatitis C virus therapy | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | closed access | es_ES |
| dc.identifier.doi | 10.1007/s00277-019-03700-3 | |
| dc.type.hasVersion | NA | es_ES |